(Updated - January 25, 2021 7:38 AM EST)Roth Capital analyst Jonathan Aschoff initiates coverage on Kempharm (NASDAQ: KMPH) with a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE